Niki BioSolutions, Inc. NIKI

NIKI Company Overview

Aptorum Group Limited is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products addressing unmet medical needs, particularly in rare (orphan) diseases, infectious diseases, and oncology. The company operates within the global biotechnology and pharmaceutical research industry, with activities spanning drug discovery, preclinical development, and early-stage clinical research.

The company’s primary revenue drivers historically have been limited, as Aptorum remains largely pre-revenue and research-focused, relying on equity financing and strategic transactions to fund operations. Its strategy emphasizes proprietary drug discovery platforms and in-licensed or repurposed compounds aimed at accelerated development pathways. Aptorum Group Limited was founded in 2015 and later completed an initial public offering on the Nasdaq Capital Market in 2018, marking its transition into a publicly traded company focused on advancing a diversified therapeutic pipeline.